Login
Intercept Pharmaceuticals NASDAQ: ICPT
Intercept Pharmaceuticals, Inc. focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases
| Name | Intercept Pharmaceuticals |
| Ticker | ICPT |
| Exchange | NASDAQ |
| Sector | Health Care |
| Industry | Biopharmaceuticals |
| Price | 28.76 |
| 52W Low/High | 28.76 / 124.10 |
| Market cap | 947 M |
| 1Y Total Return |
-61.40%
Weak |
| 1Y Volatility |
86.21%
High Risk |
Relative Strength Index : Attempt to identify overbought (above 80) and oversold (below 20) conditions
Intercept Pharmaceuticals, Inc. focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases
Details
| Ticker | ICPT |
| Name | Intercept Pharmaceuticals |
| ISIN | US45845P1084 |
| CUSIP | 45845P108 |
| Exchange | NASDAQ |
| Sector | Health Care |
| Industry | Biopharmaceuticals |
| Country | USA |
| Currency | U.S. Dollar |
| In Index(ices) | NASDAQ Biotechnology Index |
Share as of 10/28/20
| Close Price | 28.76 |
| 52W Low/High | 28.76 / 124.10 |
| Market cap | 947 M |
| 1Y Total Return |
-61.40%
Weak |
| 1Y Volatility |
86.21%
High Risk |
| Beta | 1.57 |
| PE (trailing) | - |
| 12M Dividends | - |
| Last Dividend Date | - |
| Dividend Yield | - |
Fin. Strength
| Net Profit Margin | -119.7% |
| Cash from Op. / Cur. Liabilities | -1.35 |
| Diluted Earnings / Share | -10.38 |
| ROE | - |
| ROIC | -55.6% |
| Price / Revenue | 3.3 |
| Price / Book | -12.0 |
| Price / CF | -4.3 |
| Current Ratio | 3.7 |
| Cur.Liabilities / Tot.Liabilities | 0.2 |
| Financial Leverage | - |
| in Mils USD |
rolling-year up to June
|
||||||
|---|---|---|---|---|---|---|---|
| Income Statement | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Revenue |
283
|
219
|
159
|
71
|
7
|
3
|
|
| Gross Profit |
278
|
216
|
157
|
71
|
7
|
3
|
|
| R&D |
216
|
229
|
200
|
175
|
123
|
107
|
|
| EBITDA |
-283
|
-274
|
-306
|
-353
|
-341
|
-157
|
|
| Operating Income |
-300
|
-288
|
-316
|
-362
|
-346
|
-160
|
|
| Net Income exc. Extra |
-
|
-
|
-
|
-
|
-
|
-
|
|
| per Share | |||||||
| Diluted avg Shares |
33
|
31
|
29
|
25
|
25
|
24
|
|
| EPS exc. Extra |
-10.38
|
-10.46
|
-13.11
|
-15.50
|
-14.08
|
-7.02
|
|
| Dividend |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Div. Yield (an.) |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Balance Sheet | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Total Assets |
637
|
853
|
605
|
616
|
524
|
754
|
|
| Cash, Eq & Invt ShortTerm |
541
|
759
|
538
|
550
|
484
|
732
|
|
| Total Current Assets |
607
|
819
|
578
|
579
|
505
|
741
|
|
| Total Non-Current Assets |
31
|
34
|
27
|
37
|
19
|
13
|
|
| Intangibles |
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Liabilities |
716
|
678
|
458
|
446
|
108
|
31
|
|
| Total Current Liabilities |
164
|
125
|
89
|
88
|
102
|
24
|
|
| Long Term Debt |
553
|
553
|
370
|
358
|
5
|
7
|
|
| Shareholder equity |
-79
|
175
|
147
|
170
|
417
|
723
|
|
| Cash Flow | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Cash from Operations |
-221
|
-234
|
-269
|
-334
|
-240
|
-120
|
|
| Depreciation |
9
|
7
|
5
|
4
|
3
|
1
|
|
| Cash from Investing |
180
|
-203
|
22
|
-69
|
200
|
-404
|
|
| Capex |
1
|
1
|
2
|
9
|
6
|
8
|
|
| Cash from Financing |
6
|
452
|
263
|
413
|
5
|
566
|
|
| Stock Issued |
9
|
494
|
2
|
4
|
5
|
566
|
|
| Debt (LT) Issued |
0
|
-38
|
261
|
448
|
0
|
0
|
|
| Free Cash Flow |
402
|
-474
|
-306
|
-505
|
-13
|
-544
|
|
| Ratios | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Net Profit Margin |
-
|
-
|
-
|
-
|
-
|
-
|
|
| NCFO / Op.Income |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Current Ratio |
3.7
|
6.5
|
6.5
|
6.6
|
4.9
|
31.1
|
|
| Financial Leverage D/E |
-
|
3.11
|
2.48
|
2.05
|
0.00
|
0.00
|
|
| Return on Capital Avg |
-55.6%
|
-52.4%
|
-68.7%
|
-90.1%
|
-71.0%
|
-35.3%
|
|
| Return on Shareholder Equity |
-
|
-
|
-
|
-
|
-
|
-
|
|
Fundamentals
No documents are available for the moment, please check back soon, or save the asset to be notified when documents are available